Effect of altered gastric emptying and gastrointestinal motility on metformin absorption
Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. Methods An open‐label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subjec...
Saved in:
Published in | British journal of clinical pharmacology Vol. 50; no. 4; pp. 325 - 332 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Science Ltd
01.10.2000
Blackwell Science Blackwell Science Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0306-5251 1365-2125 |
DOI | 10.1046/j.1365-2125.2000.00264.x |
Cover
Loading…
Abstract | Aims
The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects.
Methods
An open‐label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc‐DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings.
Results
Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half‐life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,∞) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival.
Conclusions
Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form. |
---|---|
AbstractList | The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects.
An open-label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc-DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings.
Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half-life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,infinity) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival.
Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form. Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. Methods An open‐label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc‐DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings. Results Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half‐life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,∞) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival. Conclusions Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form. Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. Methods An open‐label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99m Tc‐DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings. Results Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half‐life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,∞) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival. Conclusions Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form. The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects.AIMSThe purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects.An open-label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc-DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings.METHODSAn open-label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc-DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings.Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half-life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,infinity) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival.RESULTSScintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half-life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,infinity) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival.Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form.CONCLUSIONSMetformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form. |
Author | Wen, Yandong Barbhaiya, Rashmi H. Marathe, Punit H. Norton, Jean Greene, Douglas S. Wilding, Ian R. |
Author_xml | – sequence: 1 givenname: Punit H. surname: Marathe fullname: Marathe, Punit H. – sequence: 2 givenname: Yandong surname: Wen fullname: Wen, Yandong – sequence: 3 givenname: Jean surname: Norton fullname: Norton, Jean – sequence: 4 givenname: Douglas S. surname: Greene fullname: Greene, Douglas S. – sequence: 5 givenname: Rashmi H. surname: Barbhaiya fullname: Barbhaiya, Rashmi H. – sequence: 6 givenname: Ian R. surname: Wilding fullname: Wilding, Ian R. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1500685$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11012555$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUU1vFCEYJqbGbqt_wXAw3mb6wgCdTYyJbqo1aaIHTbwRhoGVDQMrsNr99zJ23aoXPUF4ny_e5wydhBgMQphAS4CJi01LOsEbSihvKQC0AFSw9vYBWhwHJ2gBHYiGU05O0VnOGwDSEcEfoVNCoCI4X6DPV9YaXXC0WPlikhnxWuWSnMZm2pa9C2uswuExulBMLi4oj6dYnHdlj2PAkyk2pskFrIYc07a4GB6jh1b5bJ4cznP06c3Vx9V1c_P-7bvVq5tGc8FYMxrLwA5q7NmyF2xUy5q517QbFBvoZc2uteAd45wYwtmoR0YJN8uh7xUFrbtz9PJOd7sbJjNqE0pSXm6Tm1Tay6ic_HMS3Be5jt8kBcIBWBV4fhBI8euufk9OLmvjvQom7rK8pHTZ9ZxU4NPfnY4Wv5ZZAc8OAJW18japoF2-x1U70fP7xDrFnJOxUrui5p3VfM5LAnIuWW7k3KWcu5RzyfJnyfK2CvR_CRwt_k19cUf97rzZ_zdPvl59qJfuB64iv9w |
CODEN | BCPHBM |
CitedBy_id | crossref_primary_10_4236_pp_2024_1512025 crossref_primary_10_1002_jps_21794 crossref_primary_10_1016_j_jddst_2017_09_013 crossref_primary_10_1016_S1359_6446_04_03351_3 crossref_primary_10_3390_pharmaceutics13111873 crossref_primary_10_3109_10717544_2015_1089957 crossref_primary_10_1007_s13318_014_0213_x crossref_primary_10_1177_00912700122010546 crossref_primary_10_1007_s00125_015_3844_9 crossref_primary_10_52711_0974_360X_2023_00814 crossref_primary_10_1208_s12249_018_1070_8 crossref_primary_10_3390_molecules22020214 crossref_primary_10_1111_jphp_12516 crossref_primary_10_1136_spcare_2023_004248 crossref_primary_10_1016_j_ijpharm_2016_11_063 crossref_primary_10_1016_j_jddst_2020_102054 crossref_primary_10_2165_11534750_000000000_00000 crossref_primary_10_2165_00024677_200403050_00008 crossref_primary_10_1016_j_jpba_2007_07_018 crossref_primary_10_1016_j_xphs_2016_11_009 crossref_primary_10_1208_s12249_009_9332_0 crossref_primary_10_1016_j_ejpb_2010_03_009 crossref_primary_10_1007_s40495_020_00230_9 crossref_primary_10_1007_s11095_022_03280_4 crossref_primary_10_1097_FTD_0b013e3181b385ba crossref_primary_10_1111_cts_12780 crossref_primary_10_2337_diacare_29_04_06_dc05_1967 crossref_primary_10_1002_psp4_13228 crossref_primary_10_1080_17425247_2021_1825375 crossref_primary_10_1007_s40262_019_00756_2 crossref_primary_10_1007_s13318_017_0418_x crossref_primary_10_1038_s41598_019_53996_4 crossref_primary_10_3109_03639045_2015_1096279 crossref_primary_10_1002_bdd_615 crossref_primary_10_1111_bcp_13049 crossref_primary_10_1016_j_clinthera_2007_05_013 crossref_primary_10_1038_s41467_021_27762_y crossref_primary_10_1016_j_ijpharm_2003_09_047 crossref_primary_10_1248_cpb_58_1295 crossref_primary_10_1371_journal_pone_0249594 crossref_primary_10_1016_j_ejpb_2018_03_002 crossref_primary_10_1124_dmd_119_088435 crossref_primary_10_1177_0091270007300949 crossref_primary_10_1002_admt_202200731 crossref_primary_10_1210_endocr_bqad139 crossref_primary_10_1016_j_clinthera_2011_10_003 crossref_primary_10_1016_j_ejps_2024_106853 crossref_primary_10_2174_1389200220666191023105609 crossref_primary_10_1007_s40264_014_0223_2 crossref_primary_10_1111_j_1464_5491_2005_01769_x crossref_primary_10_5138_ijdd_2010_0975_0215_02022 crossref_primary_10_2174_0929867329666220820151959 crossref_primary_10_1007_s00592_022_01890_3 crossref_primary_10_1021_jm030999b crossref_primary_10_2165_00003088_200544070_00004 crossref_primary_10_1007_s12010_021_03667_w crossref_primary_10_1016_j_arr_2024_102439 crossref_primary_10_1016_j_ejpb_2019_02_022 crossref_primary_10_1016_S1773_2247_10_50079_0 crossref_primary_10_2337_dc10_2140 crossref_primary_10_1016_j_carbpol_2012_05_089 crossref_primary_10_1016_j_ejpb_2007_06_004 crossref_primary_10_1016_j_ijpharm_2013_03_043 crossref_primary_10_1002_jps_23629 crossref_primary_10_3390_pharmaceutics13050698 crossref_primary_10_1016_j_ejps_2004_03_016 crossref_primary_10_1088_1757_899X_263_2_022030 crossref_primary_10_1007_s40262_017_0532_6 crossref_primary_10_1016_j_ejps_2016_08_060 crossref_primary_10_1016_j_vascn_2013_02_001 crossref_primary_10_1016_j_ijbiomac_2012_10_033 crossref_primary_10_1177_0091270004274432 crossref_primary_10_1248_bpb_b24_00566 crossref_primary_10_1371_journal_pone_0191258 crossref_primary_10_1007_s10924_019_01646_1 crossref_primary_10_1016_j_ejpb_2004_03_001 crossref_primary_10_1016_j_ijpharm_2010_04_046 crossref_primary_10_3109_10837450_2011_604783 crossref_primary_10_5487_TR_2013_29_3_173 crossref_primary_10_3109_03639045_2015_1058815 crossref_primary_10_5937_scriptamed51_25521 crossref_primary_10_1185_03007990903094361 crossref_primary_10_3389_fnut_2021_742656 crossref_primary_10_15406_japlr_2017_05_00130 crossref_primary_10_1186_s12906_017_1809_x |
Cites_doi | 10.1007/BF01059558 10.1111/j.1365-2125.1981.tb01206.x 10.1002/j.1552-4604.1992.tb03876.x 10.1002/j.1552-4604.1993.tb05612.x 10.1007/BF00315510 10.2165/00003088-199630050-00003 10.1023/A:1015849700421 10.2165/00003495-197612020-00001 10.2165/00003088-199427060-00004 10.1023/A:1015858829187 10.1023/A:1018959732744 |
ContentType | Journal Article |
Copyright | 2000 INIST-CNRS 2000 Blackwell Science Ltd 2000 |
Copyright_xml | – notice: 2000 INIST-CNRS – notice: 2000 Blackwell Science Ltd 2000 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1046/j.1365-2125.2000.00264.x |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1365-2125 |
EndPage | 332 |
ExternalDocumentID | PMC2015004 11012555 1500685 10_1046_j_1365_2125_2000_00264_x BCP264 |
Genre | article Clinical Trial Randomized Controlled Trial Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c5644-def40fbad849864da93068c23ba4b27251cc6534551e154dcd4215e9b88a20cc3 |
IEDL.DBID | DR2 |
ISSN | 0306-5251 |
IngestDate | Thu Aug 21 18:17:57 EDT 2025 Fri Jul 11 15:34:49 EDT 2025 Wed Feb 19 02:34:36 EST 2025 Mon Jul 21 09:15:52 EDT 2025 Tue Jul 01 01:47:34 EDT 2025 Thu Apr 24 23:08:47 EDT 2025 Wed Jan 22 17:05:35 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human Hypoglycemic agent Biguanides Motility Healthy subject Oral administration Gastric emptying Metformin Gastrointestinal Metabolism Pharmacokinetics Digestive transit |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5644-def40fbad849864da93068c23ba4b27251cc6534551e154dcd4215e9b88a20cc3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.2000.00264.x |
PMID | 11012555 |
PQID | 72293851 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2015004 proquest_miscellaneous_72293851 pubmed_primary_11012555 pascalfrancis_primary_1500685 crossref_citationtrail_10_1046_j_1365_2125_2000_00264_x crossref_primary_10_1046_j_1365_2125_2000_00264_x wiley_primary_10_1046_j_1365_2125_2000_00264_x_BCP264 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | October 2000 |
PublicationDateYYYYMMDD | 2000-10-01 |
PublicationDate_xml | – month: 10 year: 2000 text: October 2000 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: London – name: England |
PublicationTitle | British journal of clinical pharmacology |
PublicationTitleAlternate | Br J Clin Pharmacol |
PublicationYear | 2000 |
Publisher | Blackwell Science Ltd Blackwell Science Blackwell Science Inc |
Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell Science – name: Blackwell Science Inc |
References | 1993; 45 1992; 9 1976; 12 1993; 33 1993; 10 1984; 12 1996; 30 1994; 27 1982 1991 1992; 32 1991; 8 1981; 12 1996; 6 1983; 34 e_1_2_5_14_2 e_1_2_5_9_2 e_1_2_5_16_2 e_1_2_5_8_2 e_1_2_5_15_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_6_2 e_1_2_5_12_2 Newman SP (e_1_2_5_13_2) 1996; 6 e_1_2_5_4_2 e_1_2_5_11_2 e_1_2_5_3_2 e_1_2_5_2_2 Osmen MA (e_1_2_5_5_2) 1983; 34 |
References_xml | – year: 1982 – volume: 6 start-page: 21 year: 1996 end-page: 33 article-title: The importance of gamma scintigraphy in pharmaceutical development publication-title: J Pharm Med – volume: 10 start-page: 709 year: 1993 end-page: 714 article-title: Absorption, gastrointestinal transit, and tablet erosion of felodipine extended‐release (ER) tablets publication-title: Pharm Res – volume: 32 start-page: 725 year: 1992 end-page: 731 article-title: Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers publication-title: J Clin Pharmacol – volume: 34 start-page: 404 year: 1983 end-page: 408 article-title: Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide publication-title: Curr Ther Res – volume: 12 start-page: 649 year: 1984 end-page: 655 article-title: An exact confidence interval from untransformed data for the ratio of two treatment means publication-title: J Pharmacokin Biopharm – volume: 8 start-page: 360 year: 1991 end-page: 364 article-title: Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects publication-title: Pharm Res – volume: 30 start-page: 359 year: 1996 end-page: 371 article-title: Clinical pharmacokinetics of metformin publication-title: Clin Pharmacokin – volume: 9 start-page: 1436 year: 1992 end-page: 1441 article-title: evaluation of enteric‐coated naproxen tablets using gamma scintigraphy publication-title: Pharm Res – volume: 12 start-page: 235 year: 1981 end-page: 246 article-title: Metformin kinetics in healthy subjects and patients with diabetes mellitus publication-title: Br J Clin Pharmacol – volume: 33 start-page: 712 year: 1993 end-page: 718 article-title: Localization of drug release sites from an oral sustained‐release formulation of 5‐ASA (Pentasa ) in the gastrointestinal tract using gamma scintigraphy publication-title: J Clin Pharmacol – volume: 12 start-page: 81 year: 1976 end-page: 131 article-title: Metoclopramide. A review of its pharmacological properties and clinical use publication-title: Drugs – year: 1991 – volume: 45 start-page: 409 year: 1993 end-page: 413 article-title: Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive male and female patients publication-title: Eur J Clin Pharmacol – volume: 27 start-page: 447 year: 1994 end-page: 461 article-title: Pharmacokinetic drug interactions with gastrointestinal motility modifying agents publication-title: Clin Pharmacokin – volume: 6 start-page: 21 year: 1996 ident: e_1_2_5_13_2 article-title: The importance of gamma scintigraphy in pharmaceutical development publication-title: J Pharm Med – ident: e_1_2_5_16_2 doi: 10.1007/BF01059558 – volume: 34 start-page: 404 year: 1983 ident: e_1_2_5_5_2 article-title: Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide publication-title: Curr Ther Res – ident: e_1_2_5_2_2 doi: 10.1111/j.1365-2125.1981.tb01206.x – ident: e_1_2_5_8_2 doi: 10.1002/j.1552-4604.1992.tb03876.x – ident: e_1_2_5_10_2 doi: 10.1002/j.1552-4604.1993.tb05612.x – ident: e_1_2_5_15_2 – ident: e_1_2_5_7_2 doi: 10.1007/BF00315510 – ident: e_1_2_5_14_2 – ident: e_1_2_5_3_2 doi: 10.2165/00003088-199630050-00003 – ident: e_1_2_5_11_2 doi: 10.1023/A:1015849700421 – ident: e_1_2_5_6_2 doi: 10.2165/00003495-197612020-00001 – ident: e_1_2_5_4_2 doi: 10.2165/00003088-199427060-00004 – ident: e_1_2_5_9_2 doi: 10.1023/A:1015858829187 – ident: e_1_2_5_12_2 doi: 10.1023/A:1018959732744 |
SSID | ssj0013165 |
Score | 1.9687085 |
Snippet | Aims
The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin... Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin... The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 325 |
SubjectTerms | absorption Adult Biological and medical sciences Cross-Over Studies Dopamine Agonists - pharmacology Drug Interaction Drug Interactions Female gamma scintigraphy Gastric Emptying - physiology gastrointestinal motility Gastrointestinal Motility - physiology Hormones. Endocrine system Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - pharmacokinetics Intestinal Absorption - physiology Male Medical sciences metformin Metformin - adverse effects Metformin - pharmacokinetics Metoclopramide - pharmacology Muscarinic Antagonists - pharmacology Pharmacology. Drug treatments Propantheline - pharmacology |
Title | Effect of altered gastric emptying and gastrointestinal motility on metformin absorption |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2125.2000.00264.x https://www.ncbi.nlm.nih.gov/pubmed/11012555 https://www.proquest.com/docview/72293851 https://pubmed.ncbi.nlm.nih.gov/PMC2015004 |
Volume | 50 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS8MwEA_ikyB-f0yd5kF8smNtkrV91KH4ATJEYW8lTVIVtR2uA_Wv9y7pVqc-iPg21t7WXO6SX3N3vyNkH7YVybkQXqaN9nimwediozyf6bgTphmaDWZbXHXObvlFX_Sr_CeshXH8EJMDN_QMu16jg8vUdSFpW3bbcYYW7NC23gSPRjq8hXgSLyA-ug7qgIJvu0oiQoZ3L-FXST1VgPPHH5raqeYHcghKy1y3i5_g6Pesys9o125Xp4vkcTxQl6Xy2BqVaUu9f-GA_B9NLJGFCtXSI2eGy2TG5CvkoOdosd8O6U1d5TU8pAe0VxNmv62SvqNQpkVGbfDeaHonsZ-IouZ5UGIhFpV59WWBBBewLuH_YSIhvkbQIqfPpkT8_ZBTeOzixa6Ea-T29OSme-ZVHR88JQCYedqAcWSp1BFH2ngtY5ivSAUslTwNQpg3pTqCgW35BrCfVpoDZDFxGkUyaCvF1slsXuRmk1CdhRKWLyNNFHDGAAa2RRayWGnDmOGiQcLx7CaqokPHrhxPiQ3LcyxhQ7UmqFZs1ok0qqDW5LVB_InkwFGC_EKmOWVAtaDAIh14mr2xQSXg3xi0kbkpRsMkDACQASxukA1nXrUoUrMJgSOZMrzJDcgcPn0lf7i3DOIBnnO1eYMIa1e_HkZy3O3Bh60_ym2TOctkYHMhd8hs-TIyTcB0ZboL3np-uWt99gMzAz__ |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1RT9swED4h9rBJ08bYxrrB8APiiXRNbDfJI7ChbgNUTUXqW-TYDqBBUtFUGvv1u7PTZmU8oIm3qu0l8fnO_uK7-w5gB7cVJYSUQWGsCURh0OdSq4OQm7Qf5wWZDWVbnPYHZ-LbWI6bdkBUC-P5IRYHbuQZbr0mB6cD6U9NWNJ7uUvRwi3aFZzQ2UhfdBFQPqEG39TO4POPqA0phK6vJGFkfPuSYZPW04Q4773S0l71fKKmqLbC97u4D5D-m1f5N951G9bRS7iaD9Xnqfzszuq8q3_fYYF8JF2swYsG2LJ9b4mvYMWW67A79MzYt3ts1BZ6TffYLhu2nNm3r2HsWZRZVTAXv7eGnStqKaKZvZ7UVIvFVNl8WRHHBS5NdD_KJaQ3CVaV7NrWBMEvS6byaXXjFsM3cHb0ZXQ4CJqmD4GWiM0CY9E-ilyZRBBzvFEpTliiI54rkUcxTpzWfcnRvEKL8M9oIxC12DRPEhX1tOZvYbWsSvsOmClihSuYVTaJBOeIBHuyiHmqjeXcCtmBeD69mW4Y0akxx1XmIvOCqthIrRmplfp1EpMqqjX71YFwITnxrCAPkNlasqBWUFKdDj7N9tyiMnRxituo0lazaRZHiMkQGXdgw9tXK0rsbFLSSJYsb_EHIg9f_qW8vHAk4hEddfVEB6QzrAcPIzs4HOKH9_8ptw1PB6OT4-z46-n3D_DMERu41MhNWK1vZnYLIV6df3Su-weNK0Mg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEB6hIiEkBOUd2tI9oJ7qEHt3_ThCISoPVRFqpdys9T5KVWpHjSNRfn1ndp2YQA8V4hYlGds7O7P7eWfmG4A3uK0oIaSMnLEmEs6gzxVWRzE3RZpVjsyGsi2O0sMT8Xkqp13-E9XCBH6I1YEbeYZfr8nBZ8a97aKSwcl9hhbu0L7ehI5GUjFEPHlXpOg7BJC-JX1EIfZtJQki48uXjLusni7CeeOV1raqBzM1R6250O7iJjz6d1rl73DX71fjR3C-HGlIUzkfLtpqqH_9QQL5f1SxCQ87WMveBTt8DHds_QT2JoEX-2qfHfdlXvN9tscmPWP21VOYBg5l1jjmo_fWsFNFDUU0sxezliqxmKq7LxtiuMCFie5HmYT0HsGaml3YlgD4Wc1UNW8u_VL4DE7GH48PDqOu5UOkJSKzyFi0DlcpkwvijTeqwPnKdcIrJaokw3nTOpUcjSu2CP6MNgIxiy2qPFfJSGv-HDbqprYvgRmXKVy_rLJ5IjhHHDiSLuOFNpZzK-QAsuXslrrjQ6e2HD9KH5cXVMNGai1JrdStk3hUUa3lzwHEK8lZ4AS5hczOmgH1gpKqdPBpdpcGVaKDU9RG1bZZzMssQUSGuHgAL4J59aLEzSYljWTN8FZ_IOrw9V_qs--eQjyhg66RGID0dnXrYZTvDyb44dU_yu3CvcmHcfn109GXLbjvWQ18XuQ2bLSXC7uD-K6tXnvHvQalekHY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+altered+gastric+emptying+and+gastrointestinal+motility+on+metformin+absorption&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Marathe%2C+P+H&rft.au=Wen%2C+Y&rft.au=Norton%2C+J&rft.au=Greene%2C+D+S&rft.date=2000-10-01&rft.issn=0306-5251&rft.volume=50&rft.issue=4&rft.spage=325&rft_id=info:doi/10.1046%2Fj.1365-2125.2000.00264.x&rft_id=info%3Apmid%2F11012555&rft.externalDocID=11012555 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |